Logo

SK bioscience Collaborate with Novavax to Supply Antigen for COVID-19 Vaccine

Share this
SK bioscience Collaborate with Novavax to Supply Antigen for COVID-19 Vaccine

SK bioscience Collaborate with Novavax to Supply Antigen for COVID-19 Vaccine

Shots:

  • SK bioscience signs a development and supply agreement for Novavax’ NVX-CoV2373 to supply it globally including the COVAX facility. SK bioscience will manufacture the vaccine antigen component for use in the final drug product
  • SK bioscience will utilize its cell culture and recombinant protein capability- will initiate the production of the NVX-CoV2373 antigen at its facility in Andong L-house- South Korea- expected to begin in Aug’2020
  • Additionally- the companies have signed a letter of intent with the Republic of Korea’s Ministry of Health and Welfare for equitable access to NVX-CoV2373 in global market and to make it available in South Korea

­ Ref: PRNewswire | Image: Novavax

Click here to­ read the full press release 

Tuba

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions